Weight management, metabolic health, glucose regulation
GLP-2 (Tirzepatide)
Tirzepatide is a dual GIP and GLP-1 receptor agonist and the active ingredient in Mounjaro and Zepbound. It is FDA approved for type 2 diabetes and weight management and has demonstrated substantial effects on body weight and glucose contro
Administration Reference
Subcutaneous
Source / Evidence Context
Approved prescribing information / clinical guidance
Dose Information
dose escalation from 2.5 mg toward maintenance doses of 5, 10, or 15 mg
Frequency
Once weekly
Duration / Cycle
Ongoing treatment; no fixed end date
Timing
Any time
Storage Guidance
refrigeration after reconstitution and use within approximately 30 days, Freeze in lyophylized powder form
Supplies
Affiliate disclosure: We may earn a commission if you purchase through these links.
Listings are not a required kit or confirmation of suitability for a particular peptide, formulation, or route. Check the product specifications and intended use.
Syringes & transfer supplies
EasyTouch U-100 Insulin Syringes (31G 0.5cc 5/16″) – 100ct.U-100 Insulin Syringes (31G 0.5cc 5/16") – 100ctInsulin syringes – Polybag, 50 Unit Capacity, 5/16” Needle Length, Bold Markings for Accurate Dosing, Disposable, Box of 100View at AMAZON →
Protective supplies & disposal
MED PRIDE Sterile Alcohol Prep Pads1 BOX OF 200INDIVIDUALLY WRAPPED ISOPROPYL ALCOHOL WIPES, PACK OF 1 BOX OF 200, MEDIUM SIZE PREP PADSView at AMAZON →
Inspire Black Nitrile Gloves HEAVY DUTY 6 Mil100ctView at AMAZON →
Square Sharps Container, 2 QuartQTY 1View at AMAZON →
Commonly Reported Uses
Tirzepatide or GLP2, also known as Mounjaro, Zepbound, is known for weight management; appetite reduction; type 2 diabetes management; blood-glucose control; improvement in insulin sensitivity and cardiometabolic markers.
Commonly Reported Indicators
Reduced appetite, progressive weight loss, improved blood-glucose control, reductions in HbA1c, and improvements in waist circumference and other cardiometabolic markers.
Mechanism Overview
Tirzepatide activates both GIP and GLP-1 receptors. Together these pathways increase glucose-dependent insulin secretion, improve blood-glucose regulation, reduce appetite and food intake, and contribute to weight loss.
Safety
Safety Considerations
The source highlights gastrointestinal intolerance during dose escalation and more serious concerns including pancreatitis, gallbladder problems, kidney complications associated with dehydration, severe hypoglycemia when used with certain glucose-lowering therapies, severe allergic reactions, and thyroid-related warning signs.
Reported Adverse Effects
Nausea and other gastrointestinal side effects are commonly discussed during treatment and titration. Severe nausea or vomiting, persistent abdominal pain, hypoglycemic symptoms, kidney problems, allergic reactions, gallbladder symptoms, and severe mood changes are identified as warning signs requiring medical attention.
Contraindications & Cautions
Personal or family history of medullary thyroid carcinoma; Multiple Endocrine Neoplasia syndrome type 2 (MEN2); pregnancy or breastfeeding; history of pancreatitis.
Status
Regulatory Status
Tirzepatide is FDA approved in prescription formulations for approved indications including type 2 diabetes and chronic weight management.
Development / Research Status
Approved medication
Market Classification
Prescription medication
Status Notes
Approved prescription tirzepatide should be distinguished from lyophilized products marketed separately for research use; research-grade products are not equivalent to FDA-approved pharmaceutical formulations.
Research & Evidence
Evidence Level
Approved clinical use
Research Last Reviewed
2026-09-05
Research Overview
Tirzepatide has extensive human Phase 3 evidence supporting its effects on obesity, type 2 diabetes, weight reduction, HbA1c, and cardiometabolic outcomes. The source highlights the SURMOUNT and SURPASS clinical programs.
Human Research
SURMOUNT-1 randomized 2,539 adults with obesity or overweight without diabetes to once-weekly subcutaneous tirzepatide or placebo for 72 weeks. Mean weight reduction reached 20.9% with the 15 mg dose versus 3.1% with placebo. SURMOUNT-2 studied adults with obesity or overweight and type 2 diabetes and reported substantial weight reduction with 10 mg and 15 mg weekly dosing over 72 weeks. The SURPASS program also demonstrated significant reductions in HbA1c and body weight in people with type 2 diabetes.